SA PRO
Free Account
Denali Therapeutics Inc.DNLINASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
17 analysts·Moderate coverage
100%
Rating Distribution
Strong Buy
00%
Buy
17100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 47% higher.

Bear Case
$25.00
+11%
Consensus
$33.00
+47%
Bull Case
$40.00
+78%
Price Range17 analysts
Low
Consensus
High
$25.00
$40.00
Current Target
Current Price
$22.52
Upside to Target
$10.48

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 8, 2026Morgan Stanley
Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley
Target:$40.00
+136.0%from $16.95
Jan 7, 2026UBS
UBS Assumes Denali Therapeutics Inc. (DNLI) at Buy
Target:$25.00
+45.3%from $17.21
Dec 11, 2025Wedbush
Denali Therapeutics price target lowered to $30 from $31 at Wedbush
Target:$30.00
+70.4%from $17.61
Dec 5, 2025Wedbush
Denali Therapeutics price target raised to $31 from $30 at Wedbush
Target:$31.00
+54.2%from $20.11
Nov 17, 2025Stifel Nicolaus
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Target:$37.00
+109.4%from $17.67
Jan 7, 2025BTIG
Denali Therapeutics price target lowered to $32 from $35 at BTIG
Target:$32.00
+51.1%from $21.18
Nov 1, 2024Jefferies
Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies
Target:$45.00
+66.4%from $27.05
Oct 14, 2024BTIG
BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Target:$35.00
+25.0%from $28.00
Sep 4, 2024Bank of America Securities
Denali Therapeutics price target raised to $29 from $25 at BofA
Target:$29.00
+15.4%from $25.12
Sep 3, 2024B.Riley Financial
B.Riley Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Target:$33.00
+31.4%from $25.12
Sep 3, 2024Goldman Sachs
Goldman Sachs Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Target:$46.00
+83.1%from $25.12
Sep 3, 2024Stifel Nicolaus
Stifel Reiterates Hold Rating on Denali Therapeutics Inc. (DNLI)
Target:$22.00
-12.4%from $25.12
Aug 5, 2021Goldman Sachs
Denali Therapeutics Inc. (DNLI) PT Raised to $112 at Goldman Sachs
Target:$112.00
+111.6%from $52.93
May 18, 2021UBS
Denali Therapeutics initiated with a Buy at UBS
Target:$70.00
+26.1%from $55.51

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance